Zhihui Wang

Dr. Zhihui Wang

Mathematics in Medicine Program, The Houston Methodist Research Institute, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
PDPrashant Dogra
Prashant Dogra
NANatalie L. Adolphi
Natalie L. Adolphi
ZWZhihui Wang
Zhihui Wang
YLYu-Shen Lin
Yu-Shen Lin
KBKimberly S. Butler
Kimberly S. Butler
CBC Jeffrey Brinker
C Jeffrey Brinker
The progress of nanoparticle (NP)-based drug delivery has been hindered by an inability to establish structure-activity relationships in vivo. Here, using stable, monosized, radiolabeled, mesoporous silica nanoparticles (MSNs), we apply an integrated SPECT/CT imaging and mathematical modeling approach to understand the combined effects of MSN size, surface chemistry and routes of administration on biodistribution and clearance kinetics in healthy rats. We show that increased particle size from ~32- to ~142-nm results in a monotonic decrease in systemic bioavailability, irrespective of route of administration, with corresponding accumulation in liver and spleen. Cationic MSNs with surface exposed amines (PEI) have reduced circulation, compared to MSNs of identical size and charge but with shielded amines (QA), due to rapid sequestration into liver and spleen. However, QA show greater total excretion than PEI and their size-matched neutral counterparts (TMS). Overall, we provide important predictive functional correlations to support the rational design of nanomedicines.

4 April 2019 in Biomedical Microdevices
Verified
Journal Article
Open access
PDF file
PDPrashant Dogra
Prashant Dogra
JBJoseph D. Butner
Joseph D. Butner
YCYao-Li Chuang
Yao-Li Chuang
SCSergio Caserta
Sergio Caserta
SGShreya Goel
Shreya Goel
ZWZhihui Wang
Zhihui Wang
Cancer continues to be among the leading healthcare problems worldwide, and efforts continue not just to find better drugs, but also better drug delivery methods. The need for delivering cytotoxic agents selectively to cancerous cells, for improved safety and efficacy, has triggered the application of nanotechnology in medicine. This effort has provided drug delivery systems that can potentially revolutionize cancer treatment. Nanocarriers, due to their capacity for targeted drug delivery, can shift the balance of cytotoxicity from healthy to cancerous cells. The field of cancer nanomedicine has made significant progress, but challenges remain that impede its clinical translation. Several biophysical barriers to the transport of nanocarriers to the tumor exist, and a much deeper understanding of nano-bio interactions is necessary to change the status quo. Mathematical modeling has been instrumental in improving our understanding of the physicochemical and physiological underpinnings of nanomaterial behavior in biological systems. Here, we present a comprehensive review of literature on mathematical modeling works that have been and are being employed towards a better understanding of nano-bio interactions for improved tumor delivery efficacy.

1 September 2019 in Radiology: Artificial Intelligence
Verified
Journal Article
Closed access
AMAli Morshid
Ali Morshid
KEKhaled M. Elsayes
Khaled M. Elsayes
AKAhmed M. Khalaf
Ahmed M. Khalaf
MEMohab Elmohr
Mohab Elmohr
JYJustin Yu
Justin Yu
DFDavid Fuentes
David Fuentes
Prediction of hepatocellular carcinoma response to transcatheter arterial chemoembolization (TACE) using quantitative imaging and clinical measurements of pretreatment lesions is a potentially usef... Purpose To evaluate a fully automated machine learning algorithm that uses pretherapeutic quantitative CT image features and clinical factors to predict hepatocellular carcinoma (HCC) response to t...

14 May 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
Paola AmeroPaola Amero
Paola Amero
GLGanesh L. R. Lokesh
Ganesh L. R. Lokesh
RCRajan R. Chaudhari
Rajan R. Chaudhari
RCRoberto Cardenas-Zuniga
Roberto Cardenas-Zuniga
TSThomas Schubert
Thomas Schubert
Gabriel Lopez-BeresteinGabriel Lopez-Berestein
Gabriel Lopez-Berestein

19 December 2022 in Nature Computational Science
Verified
Journal Article
Closed access
PDF file
JBJoseph D. Butner
Joseph D. Butner
PDPrashant Dogra
Prashant Dogra
CCCaroline Chung
Caroline Chung
RPRenata Pasqualini
Renata Pasqualini
WAWadih Arap
Wadih Arap
ZWZhihui Wang
Zhihui Wang

1 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
JBJoseph D. Butner
Joseph D. Butner
DEDalia Elganainy
Dalia Elganainy
CWCharles X. Wang
Charles X. Wang
ZWZhihui Wang
Zhihui Wang
SCShu-Hsia Chen
Shu-Hsia Chen
VCVittorio Cristini
Vittorio Cristini
We present a mechanistic mathematical model of immune checkpoint inhibitor therapy to address the oncological need for early, broadly applicable readouts (biomarkers) of patient response to immunotherapy. The model is built upon the complex biological and physical interactions between the immune system and cancer, and is informed using only standard-of-care CT. We have retrospectively applied the model to 245 patients from multiple clinical trials treated with anti–CTLA-4 or anti–PD-1/PD-L1 antibodies. We found that model parameters distinctly identified patients with common (n = 18) and rare (n = 10) malignancy types who benefited and did not benefit from these monotherapies with accuracy as high as 88% at first restaging (median 53 days). Further, the parameters successfully differentiated pseudo-progression from true progression, providing previously unidentified insights into the unique biophysical characteristics of pseudo-progression. Our mathematical model offers a clinically relevant tool for personalized oncology and for engineering immunotherapy regimens.